1 result(s) displayed (1 - 1 of 1):
Drug developer Bristol-Myers Squibb Co. made another deal as it tries to focus on its pharmaceutical business, paying a 233% premium for cancer therapeutics company Kosan Biosciences. Bristol is paying $190 million cash hoping Kosan's late-stage drug Hsp90, among others, will come to market and bring in a few hundred...
Posted on May 30, 2008 7:56 AM
Movable Type search results powered by Fast Search